Miller Susan M, McPherson Ronald J, Juul Sandra E
Department of Pediatrics, University of Washington, Seattle, WA 98195, USA.
J Pediatr. 2006 Jan;148(1):44-8. doi: 10.1016/j.jpeds.2005.08.052.
To test the utility of zinc protoporphyrin to heme ratio (ZnPP/H) as an indicator of iron status in premature infants and to evaluate the effect of oral iron supplements on oxidative injury. We hypothesized that iron sulfate supplementation would decrease the ZnPP/H in preterm infants.
Infants eligible for this prospective study were: hospitalized, 24 to 32 weeks of gestation, 7 to 60 days old, feeding > or = 70 mL/kg/d, with a ZnPP/H > or = the mean for age. Iron dose was determined by the ZnPP/H. Iron status and oxidative injury were evaluated at study entry and completion. Concurrent control subjects met entry criteria but were not enrolled and were not treated with iron during the study interval. Statistical evaluation included repeated measures analysis of variance and Z-score conversions.
Entry ZnPP/H of iron-treated subjects (n = 16) and control subjects (n = 16) were not different. The ZnPP/H of iron-treated infants was lower at study end (P < .05) but did not change in control infants. Iron treatment (3 to 12 mg/kg/day) was not associated with changes in conventional measures of iron status nor in measures of oxidative injury.
Iron sulfate supplementation (3-12 mg/kg/d) decreases ZnPP/H, is tolerated, and is not associated with increased oxidative injury.
检测锌原卟啉与血红素比值（ZnPP/H）作为早产儿铁状态指标的效用，并评估口服铁补充剂对氧化损伤的影响。我们假设补充硫酸亚铁会降低早产儿的ZnPP/H。
符合这项前瞻性研究的婴儿为：住院，孕龄24至32周，7至60日龄，喂养量≥70 mL/kg/d，且ZnPP/H≥该年龄组的均值。铁剂量根据ZnPP/H确定。在研究开始和结束时评估铁状态和氧化损伤。同期对照受试者符合入选标准，但未被纳入研究，且在研究期间未接受铁剂治疗。统计评估包括重复测量方差分析和Z评分转换。
接受铁剂治疗的受试者（n = 16）和对照受试者（n = 16）的初始ZnPP/H无差异。接受铁剂治疗的婴儿在研究结束时ZnPP/H较低（P < .05），但对照婴儿的ZnPP/H未发生变化。铁剂治疗（3至12 mg/kg/天）与铁状态的传统指标变化或氧化损伤指标变化无关。
补充硫酸亚铁（3 - 12 mg/kg/d）可降低ZnPP/H，耐受性良好，且与氧化损伤增加无关。
